Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming.

Johnson LE, Brockstedt D, Leong M, Lauer P, Theisen E, Sauer JD, McNeel DG.

Oncoimmunology. 2018 May 7;7(8):e1456603. doi: 10.1080/2162402X.2018.1456603. eCollection 2018.

PMID:
30221049
2.

TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8+ T Cells.

Zahm CD, Colluru VT, McIlwain SJ, Ong IM, McNeel DG.

Cancer Immunol Res. 2018 Nov;6(11):1364-1374. doi: 10.1158/2326-6066.CIR-18-0243. Epub 2018 Sep 10.

PMID:
30201735
3.

Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer.

McNeel DG, Eickhoff JC, Wargowski E, Zahm C, Staab MJ, Straus J, Liu G.

Oncotarget. 2018 May 22;9(39):25586-25596. doi: 10.18632/oncotarget.25387. eCollection 2018 May 22.

4.

Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.

Wargowski E, Johnson LE, Eickhoff JC, Delmastro L, Staab MJ, Liu G, McNeel DG.

J Immunother Cancer. 2018 Mar 13;6(1):21. doi: 10.1186/s40425-018-0333-y.

5.

Therapeutic Cancer Vaccines: How Much Closer Are We?

McNeel DG.

BioDrugs. 2018 Feb;32(1):1-7. doi: 10.1007/s40259-017-0257-y.

PMID:
29285731
6.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

PMID:
29203590
7.

Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.

Olson BM, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, Drake CG, Weichert J, McNeel DG.

Cancer Immunol Res. 2017 Dec;5(12):1074-1085. doi: 10.1158/2326-6066.CIR-16-0390. Epub 2017 Oct 19.

PMID:
29051161
8.

89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer.

England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, Barnhart TE, McNeel DG, Huang P, Cai W.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):110-120. doi: 10.1007/s00259-017-3803-4. Epub 2017 Aug 19.

PMID:
28821924
9.

Androgen deprivation and immunotherapy for the treatment of prostate cancer.

Gamat M, McNeel DG.

Endocr Relat Cancer. 2017 Dec;24(12):T297-T310. doi: 10.1530/ERC-17-0145. Epub 2017 Aug 16. Review.

PMID:
28814451
10.

Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.

Johnson LE, Olson BM, McNeel DG.

J Immunother Cancer. 2017 Jul 18;5(1):56. doi: 10.1186/s40425-017-0260-3.

11.

Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.

Zahm CD, Colluru VT, McNeel DG.

Cancer Immunol Res. 2017 Aug;5(8):630-641. doi: 10.1158/2326-6066.CIR-16-0374. Epub 2017 Jun 20.

12.

ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.

Ehlerding EB, England CG, Majewski RL, Valdovinos HF, Jiang D, Liu G, McNeel DG, Nickles RJ, Cai W.

Mol Pharm. 2017 May 1;14(5):1782-1789. doi: 10.1021/acs.molpharmaceut.7b00056. Epub 2017 Apr 12.

13.

DNA vaccines for prostate cancer.

Zahm CD, Colluru VT, McNeel DG.

Pharmacol Ther. 2017 Jun;174:27-42. doi: 10.1016/j.pharmthera.2017.02.016. Epub 2017 Feb 7. Review.

14.

Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).

Olson BM, Bradley ES, Sawicki T, Zhong W, Ranheim EA, Bloom JE, Colluru VT, Johnson LE, Rekoske BT, Eickhoff JC, McNeel DG.

Prostate. 2017 May;77(7):812-821. doi: 10.1002/pros.23321. Epub 2017 Feb 9.

15.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.

McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL.

J Immunother Cancer. 2016 Dec 20;4:92. doi: 10.1186/s40425-016-0198-x. eCollection 2016.

16.

TCR diversity - a universal cancer immunotherapy biomarker?

McNeel DG.

J Immunother Cancer. 2016 Nov 15;4:69. eCollection 2016.

17.

Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses.

Colluru VT, Zahm CD, McNeel DG.

Oncoimmunology. 2016 Sep 2;5(10):e1223002. eCollection 2016.

18.

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M.

Clin Cancer Res. 2016 Nov 15;22(22):5461-5471. doi: 10.1158/1078-0432.CCR-15-2839. Epub 2016 May 11.

19.

Inducible expression of cancer-testis antigens in human prostate cancer.

Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, Jarrard DF, McNeel DG, Lang JM.

Oncotarget. 2016 Dec 20;7(51):84359-84374. doi: 10.18632/oncotarget.12711.

20.

B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines.

Colluru VT, McNeel DG.

Oncotarget. 2016 Oct 18;7(42):67901-67918. doi: 10.18632/oncotarget.12178.

21.

Immunotherapy for prostate cancer: False promises or true hope?

Rekoske BT, McNeel DG.

Cancer. 2016 Dec 1;122(23):3598-3607. doi: 10.1002/cncr.30250. Epub 2016 Sep 20. Review.

22.

Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.

England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W.

J Nucl Med. 2017 Jan;58(1):162-168. doi: 10.2967/jnumed.116.177857. Epub 2016 Aug 4.

23.

Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses.

Rekoske BT, Olson BM, McNeel DG.

Oncoimmunology. 2016 Mar 28;5(6):e1165377. doi: 10.1080/2162402X.2016.1165377. eCollection 2016 Jun.

24.

Molecular Imaging of Immunotherapy Targets in Cancer.

Ehlerding EB, England CG, McNeel DG, Cai W.

J Nucl Med. 2016 Oct;57(10):1487-1492. Epub 2016 Jul 28. Review.

25.

SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.

Bloom JE, McNeel DG.

Oncotarget. 2016 Aug 9;7(32):50997-51011. doi: 10.18632/oncotarget.9802.

26.

Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).

McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, DiPaola RS.

Hum Vaccin Immunother. 2015;11(10):2469-74. doi: 10.1080/21645515.2015.1062190.

27.

PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.

Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG.

Cancer Immunol Res. 2015 Aug;3(8):946-55. doi: 10.1158/2326-6066.CIR-14-0206. Epub 2015 Jun 3.

28.

Observation of long-range three-body coulomb effects in the decay of (16)Ne.

Brown KW, Charity RJ, Sobotka LG, Chajecki Z, Grigorenko LV, Egorova IA, Parfenova YL, Zhukov MV, Bedoor S, Buhro WW, Elson JM, Lynch WG, Manfredi J, McNeel DG, Reviol W, Shane R, Showalter RH, Tsang MB, Winkelbauer JR, Wuosmaa AH.

Phys Rev Lett. 2014 Dec 5;113(23):232501. Epub 2014 Dec 2.

PMID:
25526120
29.

A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R.

Cancer Immunol Res. 2014 Oct;2(10):988-99. doi: 10.1158/2326-6066.CIR-14-0073. Epub 2014 Sep 4.

30.

Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.

McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM.

Clin Cancer Res. 2014 Jul 15;20(14):3692-704. doi: 10.1158/1078-0432.CCR-14-0169. Epub 2014 May 21.

31.

DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.

Smith HA, Rekoske BT, McNeel DG.

Vaccine. 2014 Mar 26;32(15):1707-15. doi: 10.1016/j.vaccine.2014.01.048. Epub 2014 Jan 31.

32.

Preclinical and clinical development of DNA vaccines for prostate cancer.

Colluru VT, Johnson LE, Olson BM, McNeel DG.

Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Epub 2013 Dec 12. Review.

33.

Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments.

Johnson LE, Becker JT, Dubovsky JA, Olson BM, McNeel DG.

Chin Clin Oncol. 2013 Mar 1;2(1). doi: 10.3978/j.issn.2304-3865.2012.11.06.

34.

A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.

Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG.

Clin Genitourin Cancer. 2013 Dec;11(4):407-15. doi: 10.1016/j.clgc.2013.04.029. Epub 2013 Jul 5.

35.

A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells.

Casavant BP, Mosher R, Warrick JW, Maccoux LJ, Berry SM, Becker JT, Chen V, Lang JM, McNeel DG, Beebe DJ.

Methods. 2013 Dec 1;64(2):137-43. doi: 10.1016/j.ymeth.2013.05.027. Epub 2013 Jun 24.

36.

Monitoring regulatory immune responses in tumor immunotherapy clinical trials.

Olson BM, McNeel DG.

Front Oncol. 2013 May 6;3:109. doi: 10.3389/fonc.2013.00109. eCollection 2013.

37.

Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.

Becker JT, McNeel DG.

J Immunother Cancer. 2013 May 29;1:2. doi: 10.1186/2051-1426-1-2. eCollection 2013.

38.

Current controversies in the management of biochemical failure in prostate cancer.

Bruce JY, Lang JM, McNeel DG, Liu G.

Clin Adv Hematol Oncol. 2012 Nov;10(11):716-22. Review.

PMID:
23271258
39.
40.

Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.

Bloom JE, McNeel DG, Olson BM.

Expert Rev Vaccines. 2012 Dec;11(12):1401-4. doi: 10.1586/erv.12.122.

41.

Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence.

Olson BM, McNeel DG.

Expert Rev Vaccines. 2012 Nov;11(11):1315-7. doi: 10.1586/erv.12.107.

42.

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG.

J Immunol. 2012 Dec 15;189(12):5590-601. doi: 10.4049/jimmunol.1201744. Epub 2012 Nov 14.

43.

DNA Vaccines for Prostate Cancer.

McNeel DG, Becker JT, Johnson LE, Olson BM.

Curr Cancer Ther Rev. 2012 Nov 1;8(4):254-263.

44.

The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.

Olson BM, Johnson LE, McNeel DG.

Cancer Immunol Immunother. 2013 Mar;62(3):585-96. doi: 10.1007/s00262-012-1363-9. Epub 2012 Oct 30.

45.

Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.

Johnson LE, McNeel DG.

Prostate. 2012 May 15;72(7):730-40. doi: 10.1002/pros.21477. Epub 2011 Aug 30.

PMID:
22529020
46.

T cells localized to the androgen-deprived prostate are TH1 and TH17 biased.

Morse MD, McNeel DG.

Prostate. 2012 Aug 1;72(11):1239-47. doi: 10.1002/pros.22476. Epub 2011 Dec 27.

47.

Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.

McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, Liu G.

Cancer Immunol Immunother. 2012 Jul;61(7):1137-47. doi: 10.1007/s00262-011-1193-1. Epub 2011 Dec 31.

48.

Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.

Smith HA, McNeel DG.

J Immunother. 2011 Oct;34(8):569-80. doi: 10.1097/CJI.0b013e31822b5b1d.

49.

Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.

Smith HA, Cronk RJ, Lang JM, McNeel DG.

Cancer Res. 2011 Nov 1;71(21):6785-95. doi: 10.1158/0008-5472.CAN-11-2127. Epub 2011 Aug 31.

50.

Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.

Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES.

Prostate. 2012 Apr;72(5):487-98. doi: 10.1002/pros.21449. Epub 2011 Jul 11.

Supplemental Content

Loading ...
Support Center